|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US6940003B1
(en)
|
1998-12-03 |
2005-09-06 |
E. I. Du Pont De Nemours And Company |
Plan lecithin: cholesterol acyltransferases
|
|
GB9912350D0
(en)
*
|
1999-05-26 |
1999-07-28 |
European Molecular Biology Lab Embl |
Modified cytokine
|
|
FI117667B
(fi)
*
|
2001-07-05 |
2007-01-15 |
Univ Zuerich |
Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
|
|
EP2130919A1
(en)
|
2001-11-05 |
2009-12-09 |
ZymoGenetics, Inc. |
IL-21 antagonists
|
|
US7276478B2
(en)
|
2003-09-25 |
2007-10-02 |
Zymogenetics, Inc. |
Methods of treating autoimmune diseases using IL-21
|
|
KR101374454B1
(ko)
|
2005-03-31 |
2014-03-17 |
추가이 세이야쿠 가부시키가이샤 |
회합제어에 의한 폴리펩티드 제조방법
|
|
AU2006237329B2
(en)
|
2005-04-18 |
2012-04-12 |
Novo Nordisk A/S |
IL-21 variants
|
|
DK1999154T3
(da)
|
2006-03-24 |
2012-12-03 |
Merck Patent Gmbh |
Fremstillede heterodimere proteindomæner
|
|
EP2109620B1
(en)
|
2006-12-21 |
2012-08-22 |
Novo Nordisk A/S |
Interleukin-21 variants with altered binding to the il-21 receptor
|
|
EP3127921A1
(en)
*
|
2007-09-26 |
2017-02-08 |
Chugai Seiyaku Kabushiki Kaisha |
Method of modifying isoelectric point of antibody via amino acid substition in cdr
|
|
WO2009149382A2
(en)
|
2008-06-06 |
2009-12-10 |
Baylor Research Institute |
Anti-cd8 antibodies block priming of cytotoxic effectors and lead to generation of regulatory cd8+t cells
|
|
US20120107267A1
(en)
|
2009-03-11 |
2012-05-03 |
Novo Nordisk A/S |
Interleukin-21 variants having antagonistic binding to the il-21 receptor
|
|
ES2905545T3
(es)
|
2010-01-06 |
2022-04-11 |
Takeda Pharmaceuticals Co |
Proteínas de unión a calicreína plasmática
|
|
RU2013139267A
(ru)
|
2011-02-10 |
2015-03-20 |
Рош Гликарт Аг |
Улучшенная иммунотерапия
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
MY177331A
(en)
|
2012-06-15 |
2020-09-12 |
Pfizer |
Improved antagonist antibodies against gdf-8 and uses therefor
|
|
US20150191543A1
(en)
|
2012-08-06 |
2015-07-09 |
The Regents Of The University Of California |
Engineered antibody fragments for targeting and imaging cd8 expression in vivo
|
|
PL3434695T3
(pl)
|
2012-08-07 |
2021-05-17 |
Roche Glycart Ag |
Ulepszona immunoterapia
|
|
WO2014023709A1
(en)
|
2012-08-09 |
2014-02-13 |
Roche Glycart Ag |
Asgpr antibodies and uses thereof
|
|
US9580486B2
(en)
|
2013-03-14 |
2017-02-28 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of T-regulatory cells
|
|
EP3421495A3
(en)
|
2013-03-15 |
2019-05-15 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
PT3102595T
(pt)
|
2014-02-06 |
2019-01-11 |
Hoffmann La Roche |
Proteínas de fusão de interleucina-2 e suas utilizações
|
|
JP6592505B2
(ja)
|
2014-04-24 |
2019-10-16 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
インターロイキン−2のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
|
|
DK3189081T3
(da)
|
2014-09-05 |
2020-05-04 |
Janssen Pharmaceutica Nv |
Cd123-bindende midler og anvendelser deraf
|
|
WO2016100375A2
(en)
|
2014-12-15 |
2016-06-23 |
Washington University |
Compositions and methods for targeted cytokine delivery
|
|
RU2740672C2
(ru)
|
2015-08-07 |
2021-01-19 |
ЭйЭлЭкс Онколоджи Инк. |
Конструкции, имеющие sirp-альфа домен или его вариант
|
|
AU2016312259B2
(en)
|
2015-08-26 |
2018-12-06 |
Bison Therapeutics Inc. |
Multispecific antibody platform and related methods
|
|
JP7014724B2
(ja)
|
2016-02-06 |
2022-02-01 |
エピムアブ バイオセラピューティクス インコーポレイテッド |
タンデム型Fab免疫グロブリンおよびその使用
|
|
AR108034A1
(es)
|
2016-02-17 |
2018-07-11 |
Macrogenics Inc |
Moléculas de unión a ror1, y métodos de uso de las mismas
|
|
WO2018106972A1
(en)
|
2016-12-07 |
2018-06-14 |
La Jolla Institute For Allergy And Immunology |
Compositions for cancer treatment and methods and uses for cancer treatment and prognosis
|
|
CN110325205B
(zh)
|
2016-12-22 |
2023-08-15 |
库尔生物制药有限公司 |
T细胞调节性多聚体多肽及其使用方法
|
|
WO2018170096A1
(en)
|
2017-03-14 |
2018-09-20 |
Dualogics, Llc |
Use of a cd4/cd8 bispecific antibody for the treatment of diabetes
|
|
KR20240005989A
(ko)
|
2017-03-15 |
2024-01-12 |
큐 바이오파마, 인크. |
면역 반응을 조절하는 방법
|
|
CN107082812B
(zh)
|
2017-03-29 |
2018-11-13 |
上海科医联创生物科技有限公司 |
一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
|
|
WO2018209115A1
(en)
|
2017-05-10 |
2018-11-15 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
AU2018287317B2
(en)
|
2017-06-19 |
2024-06-20 |
Medicenna Therapeutics Inc. |
Uses and methods for IL-2 superagonists, agonists, and fusions thereof
|
|
US20200306301A1
(en)
|
2017-07-03 |
2020-10-01 |
Torque Therapeutics, Inc. |
Polynucleotides Encoding Immunostimulatory Fusion Molecules and Uses Thereof
|
|
CN110997013B
(zh)
|
2017-07-24 |
2022-09-20 |
瑞泽恩制药公司 |
抗cd8抗体和其用途
|
|
SG11202000820PA
(en)
|
2017-07-31 |
2020-02-27 |
Tizona Therapeutics |
Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
|
|
CN118126157A
(zh)
|
2017-08-03 |
2024-06-04 |
美国安进公司 |
白介素-21突变蛋白和治疗方法
|
|
EP3665201A4
(en)
|
2017-08-09 |
2021-06-02 |
Orionis Biosciences, Inc. |
CD8 BINDERS
|
|
WO2019033043A2
(en)
|
2017-08-11 |
2019-02-14 |
Genentech, Inc. |
ANTI-CD8 ANTIBODIES AND USES THEREOF
|
|
SG11202000387YA
(en)
|
2017-08-25 |
2020-03-30 |
Five Prime Therapeutics Inc |
B7-h4 antibodies and methods of use thereof
|
|
JP2020533971A
(ja)
|
2017-08-28 |
2020-11-26 |
アルター・バイオサイエンス・コーポレーション |
Il−15をベースとするil−7及びil−21への融合物
|
|
KR102777151B1
(ko)
|
2017-11-21 |
2025-03-05 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
인터루킨-2의 부분 효능제
|
|
US11970537B2
(en)
|
2017-12-26 |
2024-04-30 |
Nanjing GenScript Biotech Co., Ltd. |
Fusion protein dimer using antibody Fc region as backbone and use thereof
|
|
MX2020007291A
(es)
*
|
2018-01-12 |
2020-09-10 |
Amgen Inc |
Anticuerpos anti-pd-1 y metodos de tratamiento.
|
|
MX387358B
(es)
|
2018-02-28 |
2025-03-18 |
Pfizer |
Variantes de il-15 y usos de las mismas
|
|
KR20260100427A
(ko)
|
2018-03-28 |
2026-06-29 |
오리오니스 바이오사이언시즈 인코포레이티드 |
이작용성 단백질 및 이의 작제물
|
|
CA3095498A1
(en)
|
2018-04-09 |
2019-10-17 |
Origincell Therapeutics Co., Ltd. |
Anti-pd-l1 antibody and use thereof
|
|
AU2019288496B2
(en)
|
2018-06-22 |
2024-11-21 |
Cugene Inc. |
Interleukin-2 variants and methods of uses thereof
|
|
MX2020014290A
(es)
|
2018-06-22 |
2021-08-05 |
Cugene Inc |
Farmacos bioactivables a base de citoquinas y métodos de usos de los mismos.
|
|
WO2020023702A1
(en)
|
2018-07-25 |
2020-01-30 |
AskGene Pharma, Inc. |
Novel il-21 prodrugs and methods of use thereof
|
|
GB201900732D0
(en)
|
2019-01-18 |
2019-03-06 |
Ucb Biopharma Sprl |
Antibodies
|
|
JP7778571B2
(ja)
|
2019-06-05 |
2025-12-02 |
アッシャー バイオセラピューティクス, インコーポレイテッド |
免疫細胞機能をモジュレートするための変異体インターロイキン-2ポリペプチドと抗原結合分子の融合体
|
|
JP2022538139A
(ja)
|
2019-07-02 |
2022-08-31 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
変異体インターロイキン-2及び抗cd8抗体を含む免疫複合体
|
|
EP4175979A2
(en)
|
2020-07-02 |
2023-05-10 |
Inhibrx, Inc. |
Polypeptides comprising modified il-2 polypeptides and uses thereof
|
|
KR20230086765A
(ko)
|
2020-10-13 |
2023-06-15 |
얀센 바이오테크 인코포레이티드 |
분화 클러스터 iv 및/또는 viii을 조절하기 위한 바이오-조작된 t 세포 매개 면역, 물질 및 기타 방법
|
|
KR20230112632A
(ko)
|
2020-10-23 |
2023-07-27 |
애셔 바이오테라퓨틱스, 인크. |
면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합
|
|
JP2023553216A
(ja)
|
2020-12-09 |
2023-12-20 |
アシャ バイオセラピューティクス,インク. |
遺伝子操作細胞療法のための標的化サイトカイン構築物
|
|
AU2021396247A1
(en)
|
2020-12-09 |
2023-07-06 |
Asher Biotherapeutics, Inc. |
Fusions of mutant interleukin-10 polypeptides with antigen binding molecules for modulating immune cell function
|
|
WO2022135469A1
(zh)
|
2020-12-23 |
2022-06-30 |
信达生物制药(苏州)有限公司 |
白细胞介素21突变体以及其用途
|
|
WO2022245500A1
(en)
|
2021-05-19 |
2022-11-24 |
Asher Biotherapeutics, Inc. |
Il-21 polypeptides and targeted constructs
|
|
KR20230044130A
(ko)
|
2021-09-24 |
2023-04-03 |
바이오엔시스템스 주식회사 |
Pd-1 및 il-21을 포함하는 융합단백질 이량체 및 이의 용도
|
|
WO2023052846A2
(en)
|
2021-09-30 |
2023-04-06 |
Ildong Pharmaceutical Co., Ltd. |
Immunocytokine containing il-21r mutein
|